---
title: "Cyrano Therapeutics reports successful Phase 2 trial of CYR-064 for smell loss, advancing to Phase 3 in 2H 20206."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276132417.md"
description: "A recent trial successfully achieved its primary safety benchmarks and important secondary efficacy goals, leading to the decision to move forward with Phase 3 development later in the second half of 2026. The trial results were promising for Cyrano Therapeutics, Inc., a regenerative medicine company based in DELRAY BEACH, Fla. This milestone marks a significant step towards further progress in their innovative work."
datetime: "2026-02-17T13:36:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276132417.md)
  - [en](https://longbridge.com/en/news/276132417.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276132417.md)
generator: "portal-rs"
---

# Cyrano Therapeutics reports successful Phase 2 trial of CYR-064 for smell loss, advancing to Phase 3 in 2H 20206.

A recent trial successfully achieved its primary safety benchmarks and important secondary efficacy goals, leading to the decision to move forward with Phase 3 development later in the second half of 2026. The trial results were promising for Cyrano Therapeutics, Inc., a regenerative medicine company based in DELRAY BEACH, Fla. This milestone marks a significant step towards further progress in their innovative work.

### Related Stocks

- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [CYCN.US](https://longbridge.com/en/quote/CYCN.US.md)
- [CYTH.US](https://longbridge.com/en/quote/CYTH.US.md)

## Related News & Research

- [Cyclerion sets Sept. 4 record date for CVR distribution tied to Korsana merger](https://longbridge.com/en/news/297034172.md)
- [09:13 ETTranspire Bio's ANDA for Generic High-Strength Trelegy® Ellipta® Accepted for Filing by the U.S. FDA](https://longbridge.com/en/news/285949973.md)
- [bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026 | BIAF Stock News](https://longbridge.com/en/news/286107351.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**